nach oben

Current Rheumatology Reports

Erschienen in:

01.11.2017 | Orphan Diseases (B Manger, Section Editor)

Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders

verfasst von: Hasan Hashem, Susan J Kelly, Nancy J Ganson, Michael S Hershfield

Erschienen in: Current Rheumatology Reports | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

A new autoinflammatory disease, deficiency of adenosine deaminase 2 (DADA2), caused by mutations in the CECR1 gene, was first reported in 2014. This review aims to update progress in defining, treating, and understanding this multi-faceted disorder.

Recent Findings

DADA2 was first described in patients with systemic inflammation, mild immune deficiency, and vasculopathy manifested as recurrent stroke or polyarteritis nodosa (PAN). More than 125 patients have now been reported, and the phenotype has expanded to include children and adults presenting primarily with pure red cell aplasia (PRCA), or with antibody deficiency. Age of onset and clinical severity vary widely, even among related patients, and are not clearly related to CECR1 genotype. Inflammatory features often respond to anti-TNF agents, but marrow failure and severe immune deficiency may require hematopoietic stem cell transplantation.

Summary

ADA2 is expressed and secreted by monocytes and macrophages, but its biological function and the pathogenesis of DADA2 are uncertain and will remain an important area of research. Pre-clinical investigation of ADA2 replacement therapy and CECR1-directed gene therapy are warranted, but complicated by the absence of a suitable animal model.

Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol. 2017;18(8):832–42. https://doi.org/10.1038/ni.3777.CrossRefPubMed

•• Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–20. https://doi.org/10.1056/NEJMoa1307361. The first report of DADA2 as a cause of early-onset stroke. Provides experimental evidence supporting causalityof ADA2 deficiency and evidence implicating M1 macrophage polarization in pathogenesis CrossRefPubMedPubMedCentral

•• Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921–31. https://doi.org/10.1056/NEJMoa1307362. The first report of DADA2 as a cause of familial and sporadic PAN. Provides evidence of the efficacy of anti-TNF therapy in controlling autoinflammation CrossRefPubMed

Schrader WP, Pollara B, Meuwissen HJ. Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978;75(1):446–50.CrossRefPubMedPubMedCentral

Iwaki-Egawa S, Yamamoto T, Watanabe Y. Human plasma adenosine deaminase 2 is secreted by activated monocytes. Biol Chem. 2006;387(3):319–21. https://doi.org/10.1515/BC.2006.042.CrossRefPubMed

Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV, Lauvau G. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 2010;88(2):279–90. https://doi.org/10.1189/jlb.1109764.CrossRefPubMed

Zavialov AV, Engstrom A. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 2005;391(Pt 1):51–7. https://doi.org/10.1042/BJ20050683.CrossRefPubMedPubMedCentral

Zavialov AV, Yu X, Spillmann D, Lauvau G, Zavialov AV. Structural basis for the growth factor activity of human adenosine deaminase ADA2. J Biol Chem. 2010;285(16):12367–77. https://doi.org/10.1074/jbc.M109.083527.CrossRefPubMedPubMedCentral

Poursharifi P, Saghiri R, Ebrahimi-Rad M, Nazem H, Pourpak Z, Moin M, et al. Adenosine deaminase in patients with primary immunodeficiency syndromes: the analysis of serum ADA1 and ADA2 activities. Clin Biochem. 2009;42(13–14):1438–43. https://doi.org/10.1016/j.clinbiochem.2008.10.019.CrossRefPubMed

10.

Caorsi R, Penco F, Schena F, Gattorno M. Monogenic polyarteritis: the lesson of ADA2 deficiency. Pediatr Rheumatol Online J. 2016;14(1):51. https://doi.org/10.1186/s12969-016-0111-7.CrossRefPubMedPubMedCentral

11.

Berkun Y, Segel R, Navon-Elkan P. Adenosine deaminase 2 deficiency: more than monogenic vasculitis. Isr Med Assoc J. 2017;19(7):435–7.PubMed

12.

• Ozen S. The changing face of polyarteritis nodosa and necrotizing vasculitis. Nat Rev Rheumatol. 2017;13(6):381–6. https://doi.org/10.1038/nrrheum.2017.68. A thoughtful and informative recent review of PAN CrossRefPubMed

13.

Garg N, Kasapcopur O, Foster J 2nd, Barut K, Tekin A, Kizilkilic O, et al. Novel adenosine deaminase 2 mutations in a child with a fatal vasculopathy. Eur J Pediatr. 2014;173(6):827–30. https://doi.org/10.1007/s00431-014-2320-8.CrossRefPubMed

14.

• van Montfrans J, Zavialov A, Zhou Q. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478. https://doi.org/10.1056/NEJMc1405506#SA1. HSCT from a matched allogeneic donor was performed for PRCA in a patient later discovered to have DADA2. Serum ADA2 and clinical status were normal 11 years post transplant CrossRefPubMed

15.

• Van Eyck L Jr, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015;135(1):283–7 e5. https://doi.org/10.1016/j.jaci.2014.10.010. Describes the complicated course and successful HSCT in one of two siblings with DADA2, and documents elevated IL-6 in both siblings CrossRefPubMedPubMedCentral

16.

Van Eyck L, Liston A, Meyts I. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478–9. https://doi.org/10.1056/NEJMc1405506#SA2.CrossRefPubMed

17.

• Van Eyck L, Liston A, Wouters C. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):480. https://doi.org/10.1056/NEJMc1405506#SA4. DADA2 as a cause of HHV8-negativer Castleman disease, effectively treated with anti-IL6 PubMed

18.

• Bras J, Guerreiro R, Santo GC. Mutant ADA2 in vasculopathies. N Engl J Med. 2014;371(5):478–80. https://doi.org/10.1056/NEJMc1405506#SA3. DADA2 as a cause of familial Sneddon syndrome (onset of livedo racemosa and stroke in the second decade of life) CrossRefPubMed

19.

•• Belot A, Wassmer E, Twilt M, Lega JC, Zeef LA, Oojageer A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol Online J. 2014;12:44. https://doi.org/10.1186/1546-0096-12-44. Disconvery of interfereon signature and overexpression of neutrophil genes in two patients with DADA2. Suggests inflammatory features and PAN may result from chronic neutophil activation CrossRefPubMedPubMedCentral

20.

Gonzalez Santiago TM, Zavialov A, Saarela J, Seppanen M, Reed AM, Abraham RS, et al. Dermatologic features of ADA2 deficiency in cutaneous polyarteritis nodosa. JAMA Dermatol. 2015;151(11):1230–4. https://doi.org/10.1001/jamadermatol.2015.1635.CrossRefPubMed

21.

Abraham RS, Gibson LE. Error in complementary DNA nomenclature in “Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa”. JAMA Dermatol. 2016;152(9):1065. https://doi.org/10.1001/jamadermatol.2016.2595.CrossRefPubMed

22.

Westendorp WF, Nederkoorn PJ, Aksentijevich I, Hak AE, Lichtenbelt KD, Braun KP. Unexplained early-onset lacunar stroke and inflammatory skin lesions: consider ADA2 deficiency. Neurology. 2015;84(20):2092–3. https://doi.org/10.1212/WNL.0000000000001581.CrossRefPubMedPubMedCentral

23.

• Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, et al. A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol. 2015;42(8):1532–4. https://doi.org/10.3899/jrheum.150024. Highlights weak correlation between genotype and phenotype CrossRefPubMed

24.

Fellmann F, Angelini F, Wassenberg J, Perreau M, Arenas Ramirez N, Simon G, et al. IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol. 2016;137(4):1189–96 e1-2. https://doi.org/10.1016/j.jaci.2015.07.053.CrossRefPubMed

25.

Keer N, Hershfield M, Caskey T, Unizony S. Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. Rheumatology (Oxford). 2016;55(6):1145–7. https://doi.org/10.1093/rheumatology/kew050.CrossRef

26.

• Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, et al. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol. 2016;68(9):2314–22. https://doi.org/10.1002/art.39699. Highlights phenotypic heterogeneity in related patients homozygous for the same CECR1 mutation CrossRefPubMed

27.

Uettwiller F, Sarrabay G, Rodero MP, Rice GI, Lagrue E, Marot Y, et al. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open. 2016;2(1):e000236. https://doi.org/10.1136/rmdopen-2015-000236.CrossRefPubMedPubMedCentral

28.

• Ben-Ami T, Revel-Vilk S, Brooks R, Shaag A, Hershfield MS, Kelly SJ, et al. Extending the clinical phenotype of adenosine deaminase 2 deficiency. J Pediatr. 2016;177:316–20. https://doi.org/10.1016/j.jpeds.2016.06.058. Highlights PRCA and other hematologic disorders in patients with DADA2 from several Arab families CrossRefPubMed

29.

• Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 2016;55(5):902–10. https://doi.org/10.1093/rheumatology/kev439. Highlights phenotypic heterogeneity in related patients homozygous for the same CECR1 mutation CrossRef

30.

Schepp J, Bulashevska A, Mannhardt-Laakmann W, Cao H, Yang F, Seidl M, et al. Deficiency of adenosine deaminase 2 causes antibody deficiency. J Clin Immunol. 2016;36(3):179–86. https://doi.org/10.1007/s10875-016-0245-x.CrossRefPubMed

31.

• Hsu AP, West RR, Calvo KR, Cuellar-Rodriguez J, Parta M, Kelly SJ, et al. Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: successful hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2016;138(2):628–30 e2. https://doi.org/10.1016/j.jaci.2016.03.016. DADA2 as a cause of MonoMAC syndrome, successfully treated by HSCT CrossRefPubMedPubMedCentral

32.

Poswar Fde O, da Fonseca RM, de Albuquerque LC, Zhou Q, Jardim LB, Monte TL, et al. Adenosine deaminase 2 deficiency presenting as spastic paraplegia and systemic vasculitis. J Neurol. 2016;263(4):818–20. https://doi.org/10.1007/s00415-016-8070-y.CrossRefPubMed

33.

Elbracht M, Mull M, Wagner N, Kuhl C, Abicht A, Kurth I, et al. Stroke as initial manifestation of adenosine deaminase 2 deficiency. Neuropediatrics. 2017;48(2):111–4. https://doi.org/10.1055/s-0036-1597611.PubMed

34.

• Hashem H, Egler R, Dalal J. Refractory pure red cell aplasia manifesting as deficiency of adenosine deaminase 2. J Pediatr Hematol Oncol. 2017; https://doi.org/10.1097/MPH.0000000000000805. Successful HSCT for PRCA following diagnosis of DADA2

35.

• Hashem H, Vatsayan A, Gupta A, Nagle K, Hershfield M, Dalal J. Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2. Bone Marrow Transplant. 2017; https://doi.org/10.1038/bmt.2017.173.

36.

Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017; https://doi.org/10.1136/annrheumdis-2016-210802.

37.

•• Schepp J, Proietti M, Frede N, Buchta M, Hubscher K, Rojas Restrepo J, et al. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol. 2017;69(8):1689–700. https://doi.org/10.1002/art.40147. Screening idenitfied DADA2 in 11 (6%) of 181 patients with antibody deficiency (CVID) CrossRefPubMed

38.

Skrabl-Baumgartner A, Plecko B, Konig N, Hershfield M, Gruber-Sedlmayr U, Lee-Kirsch MA. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation. Pediatr Rheumatol. 2017;15(1):67. https://doi.org/10.1186/s12969-017-0193-x.

39.

Ombrello A, Stone D, Hoffmann P, Jones A, Barham B, Barron K et al. The deficiency of adenosine deaminase type 2—results of therapeutic intervention. Pediatric Rheumatology. 2015;13 (Suppl 1). doi:https://doi.org/10.1186/1546-0096-13-S1-O40.

40.

•• Hashem H, R A, Kumar AR, Müller I, Babor F, Bredius R et al. Hematopoietic stem cell transplantation rescues the hematological, immunological and vascular phenotype in DADA2. Blood. 2017, in Press. Reviews the experience with HSCT performed in 14 patients with DADA2.

41.

Azzari C, la Marca G, Resti M. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry. J Allergy Clin Immunol. 2011;127(6):1394–9. https://doi.org/10.1016/j.jaci.2011.03.040.CrossRefPubMed

42.

Richard E, Arredondo-Vega FX, Santisteban I, Kelly SJ, Patel DD, Hershfield MS. The binding site of human adenosine deaminase for CD26/dipeptidyl peptidase IV: the Arg142Gln mutation impairs binding to cd26 but does not cause immune deficiency. J Exp Med. 2000;192(9):1223–36.CrossRefPubMedPubMedCentral

43.

Homma K, Matsushita T, Natori S. Purification, characterization, and cDNA cloning of a novel growth factor from the conditioned medium of NIH-Sape-4, an embryonic cell line of Sarcophaga peregrina (flesh fly). J Biol Chem. 1996;271(23):13770–5.CrossRefPubMed

44.

Homma KJ, Tanaka Y, Matsushita T, Yokoyama K, Matsui H, Natori S. Adenosine deaminase activity of insect-derived growth factor is essential for its growth factor activity. J Biol Chem. 2001;276(47):43761–6. https://doi.org/10.1074/jbc.M105088200.CrossRefPubMed

45.

Zurovec M, Dolezal T, Gazi M, Pavlova E, Bryant PJ. Adenosine deaminase-related growth factors stimulate cell proliferation in Drosophila by depleting extracellular adenosine. Proc Natl Acad Sci U S A. 2002;99(7):4403–8. https://doi.org/10.1073/pnas.062059699.CrossRefPubMedPubMedCentral

46.

Riazi MA, Brinkman-Mills P, Nguyen T, Pan H, Phan S, Ying F, et al. The human homolog of insect-derived growth factor, CECR1, is a candidate gene for features of cat eye syndrome. Genomics. 2000;64(3):277–85. https://doi.org/10.1006/geno.1999.6099.CrossRefPubMed

47.

Charlab R, Valenzuela JG, Andersen J, Ribeiro JM. The invertebrate growth factor/CECR1 subfamily of adenosine deaminase proteins. Gene. 2001;267(1):13–22.CrossRefPubMed

48.

Kaljas Y, Liu C, Skaldin M, Wu C, Zhou Q, Lu Y, et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells. Cell Mol Life Sci. 2017;74(3):555–70. https://doi.org/10.1007/s00018-016-2357-0.CrossRefPubMed

Titel: Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders
verfasst von: Hasan Hashem
Susan J Kelly
Nancy J Ganson
Michael S Hershfield
Publikationsdatum: 01.11.2017
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 11/2017
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-017-0699-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Updates in Lupus Genetics

Chikungunya Virus-Associated Disease

Can Probiotic Supplements Improve Outcomes in Rheumatoid Arthritis?

Cardiopulmonary Manifestations of Collagen Vascular Diseases

Cannabis and Cannabinoids for Chronic Pain

Productivity Losses and Costs in the Less-Common Systemic Autoimmune Rheumatic Diseases

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin